圓通速遞國際(06123.HK)上半年純利微增1.61%至9699.2萬港元
格隆匯8月25日丨圓通速遞國際(06123.HK)公佈中期業績,截至2021年6月30日止6個月,集團收益為約30.383億港元,同比增長38.02%;公司權益股東應占期內溢利為9699.2萬港元,同比增長1.61%;基本每股盈利為23.40港仙。
於報吿期間,物流及貨運代理服務的整體需求自COVID-19疫情中大幅回升。該情況導致集團收益明顯增長,然而,貨運艙位供應有限促使集團空運貨運代理成本增加,並導致毛利減少。憑藉更好地控制費用,報吿期內的純利較2020年同期有輕微增加。
公司權益股東應占溢利增加主要歸因於集團更好地控制了費用及預期信貸虧損模型下確認的減值虧損撥回。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.